公开(公告)号：US07253151B2

公开(公告)日：2007-08-07

申请号：US10221975

申请日：2001-03-15

申请人： Young Chul Sung ,  Sung Hee Lee ,  Sang Jun Ha ,  Man Ki Song ,  Jun Chang

发明人： Young Chul Sung ,  Sung Hee Lee ,  Sang Jun Ha ,  Man Ki Song ,  Jun Chang

IPC分类号： A01N43/04 ,  A01N63/00 ,  A01N65/00 ,  A61K31/70 ,  C12N5/00 ,  C12N5/02 ,  C12Q1/68 ,  A61K38/24 ,  A61K38/27 ,  C07K1/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00

CPC分类号： C07K14/005 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/57 ,  C12N2770/24222 ,  Y02A50/412

摘要： The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12(interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the secretion of IL-12p40 but normally secretes active IL-12p70 by making mutation at Asn-222(human) or Asn-220(mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of active form of IL-12, IL-12p70. Therefore, the IL-12p40 mutant gene of the present invention can be useful for DNA vaccination and gene therapy against various diseases, for example, AIDS, hepatitis C or hepatitis B, cancer, influenza, tuberculosis and malaria, which essentially require cellular immune responses for their therapy.

摘要翻译： 本发明涉及能够产生具有高活性的人和小鼠来源的IL-12（白细胞介素12）的IL-12p40亚基突变基因，包括上述突变基因的表达载体及其用于DNA疫苗佐剂。 特别涉及抑制IL-12p40分泌的IL-12p40突变基因，但通常在IL-12p40的Asn-222（人）或Asn-220（小鼠））氨基酸上突变而分泌活性IL-12p70， 作为IL-12，IL-12p70活性形式的竞争性抑制剂。 因此，本发明的IL-12p40突变基因可用于针对各种疾病（例如艾滋病，丙型肝炎或乙型肝炎，癌症，流感，结核病和疟疾）的DNA疫苗接种和基因治疗，其基本上需要细胞免疫应答 为他们的治疗。

公开(公告)号：US07910564B2

公开(公告)日：2011-03-22

申请号：US11832993

申请日：2007-08-02

申请人： Young Chul Sung ,  Sung Hee Lee ,  Sang Jun Ha ,  Man Ki Song ,  Jun Chang

发明人： Young Chul Sung ,  Sung Hee Lee ,  Sang Jun Ha ,  Man Ki Song ,  Jun Chang

IPC分类号： A61K48/00 ,  C07H19/00 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/00 ,  A01N63/00 ,  A01N65/00

CPC分类号： C07K14/005 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/57 ,  C12N2770/24222 ,  Y02A50/412

摘要： The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12 (interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the secretion of IL-12p40 but normally secretes active IL- 12p70 by making mutation at Asn-222 (human) or Asn- 220 (mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of active form of IL-12, IL-12p70. Therefore, the IL-12p40 mutant gene of the present invention can be useful for DNA vaccination and gene therapy against various diseases, for example, AIDS, hepatitis C or hepatitis B, cancer, influenza, tuberculosis and malaria, which essentially require cellular immune responses for their therapy.

摘要翻译： 本发明涉及能够产生具有高活性的人和小鼠来源的IL-12（白细胞介素12）的IL-12p40亚基突变基因，包括上述突变基因的表达载体及其用于DNA疫苗佐剂。 特别涉及抑制IL-12p40分泌的IL-12p40突变基因，通常在IL-12p40的Asn-222（人）或Asn-220（小鼠））氨基酸上突变而分泌活性的IL-12p70， 作为IL-12，IL-12p70活性形式的竞争性抑制剂。 因此，本发明的IL-12p40突变基因可用于针对各种疾病（例如艾滋病，丙型肝炎或乙型肝炎，癌症，流感，结核病和疟疾）的DNA疫苗接种和基因治疗，其基本上需要细胞免疫应答 为他们的治疗。